Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Has the Sotrovimab Or Xevudy Market Growth Performance Trended Historically, And What Lies Ahead?

The market size of sotrovimab or xevudy has experienced a HCAGR of XX over the recent years. From 2024 to 2025, this market is projected to grow from $XX million to $XX million, with a compound annual growth rate (CAGR) of XX%. The historic growth surge can be correlated to the increased prevalence of COVID-19, heightened demand for efficient monoclonal antibody treatments, elevated awareness regarding care for high-risk patients, augment in government funding, and an increase in partnerships amongst pharmaceutical corporations.

In the upcoming years, we anticipate a XX (FCAGR) increase in the sotrovimab or xevudy market, expected to reach $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. This expected growth during the forecast period is due to various factors like the rising presence of new COVID-19 variants, increased attention to monoclonal antibody cures, development of healthcare accessibility in burgeoning regions, growing governmental aid for preparatory measures for pandemics, and the expansion of telehealth services for treatment provision. Noteworthy trends during this period will be the progress in vaccine production technologies, innovative formulations, telehealth integration, enhancements in antibody generation technologies, and advancement in the field of antibody engineering.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

Which Primay Drivers Are Accelerating Growth in the Sotrovimab Or Xevudy Market?

The escalating number of COVID-19 cases is projected to spur the expansion of the sotrovimab, also known as xevudy, market in future. COVID-19, a disease instigated by the SARS-CoV-2 virus, is transmitted via respiratory droplets and brings about symptoms ranging from a light fever to serious respiratory complications. Its proliferation can be hindered by vaccines and sanitation practices. A growth in COVID-19 instances can be attributed to factors like emerging strains of the virus, diminishing immunity, relaxed safety measures, seasonal indoor congregations, and unequal distribution of vaccines. Sotrovimab is employed to treat high-risk COVID-19 patients by combating the virus at an early stage, thus averting extreme results such as hospitalizations or fatalities. For example, in March 2023, a study released by the Office for National Statistics, a UK governmental department for official statistics, stated that approximately 1.9 million people in the UK (which is 2.9% of the populace) reported having COVID. A majority of them (92%) had contracted COVID-19 more than 12 weeks ago, with 69% suffering from symptoms for over a year and 41% for beyond two years. Therefore, the upswing in the prevalence of COVID cases will fuel the growth of the sotrovimab or xevudy market.

Which Primary Segments of the Sotrovimab Or Xevudy Market Are Driving Growth and Industry Transformations?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric; Adult; Geriatric

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

Which Regions Are Key Players in the Growth of the Sotrovimab Or Xevudy Market?

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing the Sotrovimab Or Xevudy Industry Evolution?

Strategic investments intended to amplify research, enlarge production capabilities, and enhance drug accessibility are defining the sotrovimab or xevudy market’s current trajectory. These initiatives are significant for expediting distribution and ensuring larger scale availability, especially in areas where the need is substantial. In January 2022, for example, UK-based GSK plc collaborated with US-based Vir Biotechnology Inc., to finalize an impactful deal with the United States government to procure additional sotrovimab supplies – a monoclonal antibody permitted for early COVID-19 treatment. This deal affirms the continuous demand for effective cures while the pandemic keeps mutating. Sotrovimab has been specifically developed for adults and young adults who are at high risk of developing severe COVID-19 and is a crucial resource for those who have not yet required oxygen support. This recent collaboration mirrors GSK and Vir’s wider strategy to maintain the accessibility of sotrovimab amidst the advent of new COVID-19 strains.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

What Parameters Are Used to Define the Sotrovimab Or Xevudy Market?

Sotrovimab (Xevudy) is a monoclonal antibody treatment developed for the management of COVID-19. It is specifically designed to target the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used for treating mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, offering an effective therapeutic option in early-stage infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model